Candel Therapeutics, Inc. Common Stock
CADLCandel Therapeutics, Inc. (CADL) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for the treatment of cancer. The company leverages its proprietary oncolytic viral platform to design and develop therapies aimed at stimulating the immune system to recognize and destroy tumors, with a focus on translating these therapies into effective solutions for patients with various types of cancer.
Company News
The global oncolytic virotherapy market is projected to grow from USD 49.73 million in 2025 to USD 153.31 million by 2031, with a CAGR of 20.64%. Growth is driven by rising cancer incidence, advances in genetic engineering, and synergistic combination therapies with checkpoint inhibitors. However, host immune system challenges and premature viral...
Candel Therapeutics presented three key research presentations at SITC 2025, highlighting advances in immunotherapy for solid tumors using multi-omics analysis and artificial intelligence, including promising phase 3 clinical trial results for CAN-2409 in prostate cancer and preclinical data from their enLIGHTENâ„¢ Discovery Platform.
Candel Therapeutics published positive phase 1b clinical trial data on the combination of CAN-2409 and nivolumab plus standard of care in newly diagnosed high-grade glioma patients, demonstrating a promising safety profile and potential survival benefit.
Candel Therapeutics, a clinical-stage biopharmaceutical company, has appointed Elizabeth M. Jaffee, M.D., a renowned expert in pancreatic cancer and immunology, to its Research Advisory Board. This appointment aligns with Candel's focus on developing multimodal biological immunotherapies for cancer treatment, particularly in borderline resectable...
Candel Therapeutics, a clinical-stage biopharmaceutical company, announced the launch of an $80 million public offering of its common stock and pre-funded warrants. The company plans to use the proceeds to continue the development of its product candidates, including preparing the submission of a Biologics License Application for CAN-2409 in pros...
